This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Zhejiang API maker receives pre-penalty notice for price fixing from Chinese regulator

By MLex Staff ( April 28, 2025, 07:53 GMT | Insight) -- Xianju Pharmaceutical, a Zhejiang-based drug manufacturer listed in Shenzhen, received a pre-penalty notice in April from the Tianjin market regulator for alleged price fixing. According to the company's latest annual report, the Tianjin antitrust authority plans to impose a fine of 171.5 million yuan ($23.4 million) for reaching and implementing monopolistic agreements in the market for the active pharmaceutical ingredient dexamethasone sodium phosphate. In addition, the regulator will confiscate 23.7 million yuan in alleged illegal gains.Xianju Pharmaceutical, a Zhejiang-based drug manufacturer listed in Shenzhen, received a pre-penalty notice in April from the Tianjin market regulator for alleged price fixing....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections